Via Nova Therapeutics
Latest round
- Series A
Last raised
- Aug 2021
Total raised
- $5M
Investors
- 1
About Via Nova Therapeutics
Founded in 2020 and based in California, US, Via Nova Therapeutics, Inc. operates as a biotechnology company for developing and discovering treatments for acute and subacute viral infections. The company was co-founded by Kelly Wong and Virologists Don Ganem. The company discovers and develops therapeutics for acute and subacute viral infections. Via Nova Therapeutics targets fundamental mechanisms of viral replication and supports the discovery of novel therapeutics for other viral infections as well.
Who invested in Via Nova Therapeutics
1 investor across 1 round
See all investors in Via Nova Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Aug 31, 2021
Amount
$5M
Investors
Questions about Via Nova Therapeutics
Who invested in Via Nova Therapeutics?
Via Nova Therapeutics has 1 investor on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Via Nova Therapeutics raised?
Via Nova Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Via Nova Therapeutics last raise money?
Via Nova Therapeutics's most recent round on record is a Series A, in Aug 2021.
What does Via Nova Therapeutics do?
Founded in 2020 and based in California, US, Via Nova Therapeutics, Inc.
Where is Via Nova Therapeutics headquartered?
Via Nova Therapeutics is headquartered in San Francisco, US.
Which VCs invest in companies like Via Nova Therapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Via Nova Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Via Nova Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.